UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 10, 2004



                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)


           Florida                        0-27937                 65-0142474
           -------                        -------                 ----------
(State or Other Jurisdiction of    (Commission File Number)     (IRS Employer
           Incorporation)                                    Identification No.)


    1055 Hastings Street, Suite 1900
      Vancouver, British Columbia                               V6E 2E9
      ----------------------------                              -------
        (Address of Principal Executive Offices)               (Zip Code)


                                 (604) 669-8817
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[X]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

Item 8.01   Other Events

     The purpose of this current  report on Form 8-K is to disclose  that Dragon
Pharmaceutical  Inc. issued a press release on December 10, 2004 announcing that
it has retained the services of Renmark Financial  Communications Inc. to handle
its investor relations  activities.  The press release is attached as an exhibit
to this Form 8-K.

Item 9.01   Financial Statements and Exhibits

     (c)    Exhibits 99.1 Press release dated December 10, 2004.



                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  December 10, 2004            DRAGON PHARMACEUTICAL INC.

                                    /s/ Matthew Kavanagh
                                    --------------------------------------------
                                    Matthew Kavanagh
                                    Director of Finance and Compliance
                                    (Principal Financial and Accounting Officer)


<PAGE>
                                                                  Exhibit 99.1

                   Dragon retains Renmark Financial to serve
                      the Professional Investment Community

Vancouver,  B.C., December 10, 2004 - Dragon  Pharmaceutical Inc. (OTC BB: DRUG;
TSX:  DDD;  BBSE:  DRP)  announces  that it has retained the services of Renmark
Financial  Communications  Inc. to handle its investor relations  activities for
investment brokers and advisors across the U.S. and Canada.

Renmark Financial will proactively  articulate  Dragon's  corporate messages and
growth potential to professional investment brokers and advisors across U.S. and
Canada.  In addition,  Dragon's  management  team will also attend  presentation
sessions  organized by Renmark  Financials  across North  America to address the
target  audience  upon the  completion of the proposed  acquisition  of Oriental
Wave.

"We are pleased to announce that we have selected Renmark to strengthen Dragon's
profile  amongst the North  American  financial  community.  We will continue to
participate  in  additional   investor  relations   functions  to  increase  the
visibility of our company.  We believe that Renmark Financial will be able to do
so with its unique investor  relations  strategies and approach."  commented Dr.
Alexander Wick, President and Chief Executive Officer of Dragon Pharmaceutical.

About Dragon  Pharmaceutical Inc.
Dragon  Pharmaceutical  Inc.  is  an  international  bio-pharmaceutical  company
headquartered in Vancouver,  Canada,  with a GMP production facility in Nanjing,
China.  Dragon's EPO products are being marketed in 9 countries:  China,  India,
Egypt,  Brazil, Peru, Ecuador,  Trinidad-Tobago,  Dominican Republic and Kosovo.
Additional regulatory submissions are in progress throughout Central and Eastern
Europe,  Asia,  Latin  America,  the Middle East and Africa,  and the Company is
preparing to enter the European Union market.

Dragon  Pharmaceutical  Inc. announced  entering into a definitive  agreement to
acquire  Oriental Wave Holdings  Ltd. The proposed  acquisition  is subject to a
number of  conditions  including  shareholders'  vote to  approve  the  proposed
acquisition,  which has been  scheduled  on January 11,  2005.  If the  proposed
acquisition is  consummated,  the combined  company will have diverse and proven
product  lines  under 3  divisions:  a  Pharma  division  for  prescription  and
over-the-counter  generic  drugs,  a Chemical  division for bulk  pharmaceutical
chemicals such as Clavulanic  Acid,  7-ACA and sterilized bulk drug  production,
and a  Biotech  division  for EPO and  in-licensed  G-CSF.  Please  refer to the
Company's proxy statement filed with the SEC.

Forward Looking Statement:
Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private
Securities Litigation Reform Act of 1995: All statements,  other than historical
facts,   included  in  this  press  release  are   forward-looking   statements.
Forward-looking  statements  are not  guarantees  of  future  performance.  They
involve risk,  uncertainties  and  assumptions  including  risks discussed under
"Risks Associated With Dragon  Pharmaceutical" in the Company's annual report on
Form 10-KSB,  SEC File No.: 0- 27937 and other documents filed with the SEC. The
Company  does  not   undertake   the   obligation   to  publicly   revise  these
forward-looking statements to reflect subsequent events or circumstances.

The foregoing  may be deemed to be soliciting  materials of Dragon in connection
with its  definitive  agreement to acquire  Oriental Wave  announced on June 14,
2004.  This  disclosure is being made in connection with Regulation of Takeovers
and Security Holder  Communications  (Release Nos. 33-7760 and 34-42055) adopted
by the  Securities  and  Exchange  Commission  ("SEC") and Rule 14a-12 under the
Securities  Exchange  Act of 1934,  as amended.  Dragon  shareholders  and other
investors are urged to read the  definitive  proxy  statement  that Dragon filed
with the SEC and sent to shareholders  in connection with the proposed  business
acquisition  because it contains  important  information about Dragon,  Oriental
Wave and related matters. Dragon and its directors and executive officers may be

<PAGE>
deemed to be  participants  in  Dragon's  solicitation  of proxies  from  Dragon
shareholders in connection with the proposed acquisition.  Information regarding
the participants and their security holdings can be found in Dragon's definitive
proxy statement filed with the SEC. The definitive  proxy statement is available
for  free,  both on the SEC web site  (http://www.sec.gov)  and from  Dragon  as
follows:

Garry Wong
Dragon Pharmaceutical, Inc
1900 -1055 West Hastings Street, Vancouver, British Columbia, Canada V6E 2E9
Telephone: (604) 669-8817 or North America Toll Free: 1-877-388-3784

For further information please contact:

Dragon Pharmaceutical Inc.
Garry Wong

or

Renmark Financial Communications Inc.
John Boidman : jboidman@renmarkfinancial.com
Sylvain Laberge : slaberge@renmarkfinancial.com
Media - Cynthia Lane : clane@renmarkfinancial.com
Tel. : (514) 939-3989 Fax : (514) 939-3717 www.renmarkfinancial.com
[{"type": "8-K", "sequence": "1", "filename": "pressrelease121004.txt", "description": "FOR PRESS RELEASE ON DECEMBER 10, 2004", "secsgml_size_bytes": 8257}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICALS INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "041197131"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): December 10, 2004

                           DRAGON PHARMACEUTICAL INC.
             (Exact name of registrant as specified in its charter)

           Florida                        0-27937                 65-0142474
           -------                        -------                 ----------
(State or Other Jurisdiction of    (Commission File Number)     (IRS Employer
           Incorporation)                                    Identification No.)

    1055 Hastings Street, Suite 1900
      Vancouver, British Columbia                               V6E 2E9
      ----------------------------                              -------
        (Address of Principal Executive Offices)               (Zip Code)

                                 (604) 669-8817
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[X]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
Item 8.01   Other Events

     The purpose of this current  report on Form 8-K is to disclose  that Dragon
Pharmaceutical  Inc. issued a press release on December 10, 2004 announcing that
it has retained the services of Renmark Financial  Communications Inc. to handle
its investor relations  activities.  The press release is attached as an exhibit
to this Form 8-K.

Item 9.01   Financial Statements and Exhibits

     (c)    Exhibits 99.1 Press release dated December 10, 2004.

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  December 10, 2004            DRAGON PHARMACEUTICAL INC.

                                    /s/ Matthew Kavanagh
                                    --------------------------------------------
                                    Matthew Kavanagh
                                    Director of Finance and Compliance
                                    (Principal Financial and Accounting Officer)
Exhibit 99.1

                   Dragon retains Renmark Financial to serve
                      the Professional Investment Community

Vancouver,  B.C., December 10, 2004 - Dragon  Pharmaceutical Inc. (OTC BB: DRUG;
TSX:  DDD;  BBSE:  DRP)  announces  that it has retained the services of Renmark
Financial  Communications  Inc. to handle its investor relations  activities for
investment brokers and advisors across the U.S. and Canada.

Renmark Financial will proactively  articulate  Dragon's  corporate messages and
growth potential to professional investment brokers and advisors across U.S. and
Canada.  In addition,  Dragon's  management  team will also attend  presentation
sessions  organized by Renmark  Financials  across North  America to address the
target  audience  upon the  completion of the proposed  acquisition  of Oriental
Wave.

"We are pleased to announce that we have selected Renmark to strengthen Dragon's
profile  amongst the North  American  financial  community.  We will continue to
participate  in  additional   investor  relations   functions  to  increase  the
visibility of our company.  We believe that Renmark Financial will be able to do
so with its unique investor  relations  strategies and approach."  commented Dr.
Alexander Wick, President and Chief Executive Officer of Dragon Pharmaceutical.

About Dragon  Pharmaceutical Inc.
Dragon  Pharmaceutical  Inc.  is  an  international  bio-pharmaceutical  company
headquartered in Vancouver,  Canada,  with a GMP production facility in Nanjing,
China.  Dragon's EPO products are being marketed in 9 countries:  China,  India,
Egypt,  Brazil, Peru, Ecuador,  Trinidad-Tobago,  Dominican Republic and Kosovo.
Additional regulatory submissions are in progress throughout Central and Eastern
Europe,  Asia,  Latin  America,  the Middle East and Africa,  and the Company is
preparing to enter the European Union market.

Dragon  Pharmaceutical  Inc. announced  entering into a definitive  agreement to
acquire  Oriental Wave Holdings  Ltd. The proposed  acquisition  is subject to a
number of  conditions  including  shareholders'  vote to  approve  the  proposed
acquisition,  which has been  scheduled  on January 11,  2005.  If the  proposed
acquisition is  consummated,  the combined  company will have diverse and proven
product  lines  under 3  divisions:  a  Pharma  division  for  prescription  and
over-the-counter  generic  drugs,  a Chemical  division for bulk  pharmaceutical
chemicals such as Clavulanic  Acid,  7-ACA and sterilized bulk drug  production,
and a  Biotech  division  for EPO and  in-licensed  G-CSF.  Please  refer to the
Company's proxy statement filed with the SEC.

Forward Looking Statement:
Cautionary Statement for Purposes of the "Safe Harbor" Provisions of the Private
Securities Litigation Reform Act of 1995: All statements,  other than historical
facts,   included  in  this  press  release  are   forward-looking   statements.
Forward-looking  statements  are not  guarantees  of  future  performance.  They
involve risk,  uncertainties  and  assumptions  including  risks discussed under
"Risks Associated With Dragon  Pharmaceutical" in the Company's annual report on
Form 10-KSB,  SEC File No.: 0- 27937 and other documents filed with the SEC. The
Company  does  not   undertake   the   obligation   to  publicly   revise  these
forward-looking statements to reflect subsequent events or circumstances.

The foregoing  may be deemed to be soliciting  materials of Dragon in connection
with its  definitive  agreement to acquire  Oriental Wave  announced on June 14,
2004.  This  disclosure is being made in connection with Regulation of Takeovers
and Security Holder  Communications  (Release Nos. 33-7760 and 34-42055) adopted
by the  Securities  and  Exchange  Commission  ("SEC") and Rule 14a-12 under the
Securities  Exchange  Act of 1934,  as amended.  Dragon  shareholders  and other
investors are urged to read the  definitive  proxy  statement  that Dragon filed
with the SEC and sent to shareholders  in connection with the proposed  business
acquisition  because it contains  important  information about Dragon,  Oriental
Wave and related matters. Dragon and its directors and executive officers may be
deemed to be  participants  in  Dragon's  solicitation  of proxies  from  Dragon
shareholders in connection with the proposed acquisition.  Information regarding
the participants and their security holdings can be found in Dragon's definitive
proxy statement filed with the SEC. The definitive  proxy statement is available
for  free,  both on the SEC web site  (http://www.sec.gov)  and from  Dragon  as
follows:

Garry Wong
Dragon Pharmaceutical, Inc
1900 -1055 West Hastings Street, Vancouver, British Columbia, Canada V6E 2E9
Telephone: (604) 669-8817 or North America Toll Free: 1-877-388-3784

For further information please contact:

Dragon Pharmaceutical Inc.
Garry Wong

or

Renmark Financial Communications Inc.
John Boidman : jboidman@renmarkfinancial.com
Sylvain Laberge : slaberge@renmarkfinancial.com
Media - Cynthia Lane : clane@renmarkfinancial.com
Tel. : (514) 939-3989 Fax : (514) 939-3717 www.renmarkfinancial.com